Canopy Growth (FRA:11L) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:11L Canopy Growth Corp FRA:11L
59 GF Score
Price €0.83
GF Value €0.67
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Canopy Growth Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Canopy Growth's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:11L vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canopy Growth Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Canopy Growth's Margin of Safety % (DCF Earnings Based) falls into.


FRA:11L
59GF Score
Canopy Growth Corp FRA:11L
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canopy Growth (FRA:11L) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of €0.83 is trading 23.9% above its estimated GF Value™ of €0.67. GuruFocus considers Canopy Growth to be Modestly Overvalued.

Key valuation signals for FRA:11L:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.67 vs. price of €0.83 (23.9% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score

Get the complete analysis for FRA:11L

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.83
Price
€0.67
GF Value